Rheumatoid Arthritis

Another state passes legislation to increase uptake of biosimilars.

Filgotinib may offer new option for patients with rheumatoid arthritis who have an inadequate response to methotrexate.

Top articles of the week from Specialty Pharmacy Times.

Both 15-mg and 30-mg doses of upadacitinib achieved desired endpoints in the treatment of rheumatoid arthritis.

Sandoz is seeking approval of biosimilars adalimumab and infliximab for use in all indications of their respective reference products.

Initiating biologics before triple therapy increases costs and provides minimal incremental benefit.

Switching from DMARDs to first-line biologics may not be the optimal treatment for RA.

RA patients can consume up to 14 alcoholic beverages per week without increasing the risk of liver damage, but rates increase with increasing levels of alcohol consumption.

Metastatic urothelial carcinoma drug among key approvals from May 2017.

Kevin Mange, MD, MSCE, head of North America Medical Immunology at Sanofi, provides a comprehensive overview of the considerations in the treatment of rheumatoid arthritis, which carries comorbidities that affect multiple organ systems.

Top articles of the week from The American Journal of Pharmacy Benefits.

Age-associated B cells found to contribute to autoimmune disorder prevalence in women.

Sarilumab plus DMARDs demonstrated statistically significant improvements in patients with moderate to severe RA.

Sarilumab is a human monoclonal antibody designed to bind to the interleukin-6 receptor.

The FDA has approved sarilumab (Kevzara) from Sanofi and Regeneron Pharmaceuticals for the treatment of adult patients with moderately to severely active rheumatoid arthritis.

Altered stem cells are capable of developing into cartilage cells that create a biologic anti-inflammatory drug.

Interstitial lung disease, a common complication of rheumatoid arthritis, often leads to deteriorating health.

Auranofin is a gold-containing drug used to alleviate the symptoms of rheumatoid arthritis.

Drug combination increases the efforts of killing cancer cells.

Patient engagement and involvement found to be crucial to in effective rheumatoid arthritis treatment.

FDA requires more clinical data for approval of baricitinib in moderate-to-severe rheumatoid arthritis.

FDA requires additional clinical data to determine the most appropriate doses of Olumiant (baricitinib) for the treatment of rheumatoid arthritis (RA).

Sirukumab is a human monoclonal antibody that selectively binds to the interleukin-6 cytokine with high affinity in RA.

The rheumatoid arthritis (RA) drug market is projected to reach approximately $28.5 billion by 2025.

Top five most popular articles this week on Specialty Pharmacy Times.

Heart failure higher among RA patients independent of their risk for ischemic heart disease.

Novel drug well-tolerated in patients with active RA who were refractory.

Synovial CD4+ T cells that produce IL-21 play a role in joint inflammation.

Efficacy of tocilizumab monotherapy was maintained or improved for up to 264 weeks.

More patients treated with baricitinib achieved ACR50 and ACR70 compared with Humira.